These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 19038100)

  • 1. [New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
    Bobé P; Chelbi-Alix MK
    Med Sci (Paris); 2008 Nov; 24(11):967-71. PubMed ID: 19038100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
    Bobé P; Bonardelle D; Benihoud K; Opolon P; Chelbi-Alix MK
    Blood; 2006 Dec; 108(13):3967-75. PubMed ID: 16926289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
    J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
    Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
    Sui M; Zhang Z; Zhou J
    Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P
    J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute promyelocytic leukemia with arsenic trioxide.
    Conrad ME
    N Engl J Med; 1999 Apr; 340(13):1043-5. PubMed ID: 10189286
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia.
    Keyhani M
    J Clin Oncol; 2012 Jan; 30(2):217; author reply 218-20; discussion 220-2. PubMed ID: 22124099
    [No Abstract]   [Full Text] [Related]  

  • 12. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
    Haanen C; Vermes I
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arsenic trioxide as a therapeutic agent in APL].
    Emi N
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():724-8. PubMed ID: 17474483
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T; Westervelt P; Hess JL
    Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
    Powell BL
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1317-9. PubMed ID: 21929304
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 17. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
    Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
    Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lo Coco F
    Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
    [No Abstract]   [Full Text] [Related]  

  • 19. [Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].
    Moreno Tejero ML; Lassaletta Atienza A; García Salido A; Sevilla Navarro J; Madero López L
    An Pediatr (Barc); 2010 Jul; 73(1):39-41. PubMed ID: 20605542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research advances on effect of arsenic trioxide on tumor].
    Feng CQ; Ma WL; Zheng WL
    Ai Zheng; 2002 Dec; 21(12):1386-9. PubMed ID: 12520754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.